Answer
Alyftrek is indicated from 6 years of age for people with cystic fibrosis who have at least one F508del mutation or another responsive CFTR mutation.
Sources for this answer
- Alyftrek 50 mg/20 mg/4 mg film-coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 4Document updated
Sources checked